icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
Ledipasvir/Sofosbuvir Retreating Prior Failures Phase 3
 
 
  EASL: Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)
 
EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)
 
EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver
London, United Kingdom
April 9-13